Dendritic Nanotechnologies and Lumera Sign Joint Research Agreement

    MOUNT PLEASANT, Mich., Nov. 10 /PRNewswire/ -- Dendritic Nanotechnologies
 Inc. (DNT), a company focused on the discovery, development, and
 commercialization of dendrimer technologies to create a new generation of
 innovative products for the identification and treatment of human diseases,
 and Lumera have entered into a joint research agreement to co-develop certain
 proprietary surface chemistries suitable for specific applications of Lumera's
 label-free array reader, ProteomicProcessor(TM).
     Under the terms of this agreement, DNT will build chemistries on
 proprietary Lumera surfaces, focusing efforts on using their expertise and
 patent holdings in the area of dendrimers. Lumera will use their proprietary
 instrument designs and biological systems to test and evaluate the
 dendrimer-based approaches. It is expected that the combined expertise of
 Lumera in optically active polymers, defined surfaces and label-free detection
 systems, and the dendrimer expertise of Dendritic Nanotechnologies, will
 result in unique performance features and benefits for proteomic applications.
 Terms of the agreement were not disclosed.
     "This research agreement with Lumera is an important milestone for DNT
 since it represents one of the first commercial applications of our recently
 announced Priostar dendrimers," said Robert Berry, DNT's chief executive
 officer.
     DNT's new dendrimer technology is called Priostar(TM) and offers a
 significant advantage over other precision nanostructures by reducing the
 complexity and duration of the synthesis process. The new Priostar family of
 scalable, precision dendrimers breaks through previous cost barriers and
 addresses industry needs for nanostructures that can be manufactured in high
 volumes at costs attractive for a wide variety of uses.
 
     About Lumera
     Lumera is an emerging leader in the field of nanotechnology. The company
 designs proprietary molecular structures and polymer compounds for the
 bioscience and communications/computing industries, both of which represent
 large market opportunities. The company also has developed proprietary
 processes for fabricating such devices. For more information, please visit
 www.lumera.com.
 
     About DNT
     Dendritic Nanotechnologies Inc. (DNT) is focused on the discovery,
 development, and commercialization of dendrimer technologies to create a new
 generation of innovative products for the identification and treatment of
 human diseases. DNT's proprietary dendrimer platform serves as a targeted
 diagnostic and therapeutic delivery system for a wide variety of drugs to
 cancer cells and other diseases. Improved efficacy, enhanced solubility, and
 lower toxicity have been demonstrated for many existing drugs. DNT is
 committed to producing commercially viable dendrimers that can be manufactured
 in large quantities, and to driving down manufacturing complexity and costs.
 The company has a patent pending on its Priostar(TM) family of dendrimers, a
 novel dendrimer family that breaks through previous cost and manufacturing
 barriers.
 
 

SOURCE Dendritic Nanotechnologies Inc.

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.